Cargando…
Progressive bevacizumab-associated renal thrombotic microangiopathy*
Vascular endothelial growth factor (VEGF) is integral to the integrity of the glomerular filtration barrier. Bevacizumab is a humanized monoclonal antibody directed against VEGF with expanding clinical applications for metastatic solid tumours. We describe a case of a 61-year-old female with ovarian...
Autores principales: | Uy, Alice L., Simper, Novae B., Champeaux, Anne L., Perkins, Robert M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421476/ https://www.ncbi.nlm.nih.gov/pubmed/25949282 http://dx.doi.org/10.1093/ndtplus/sfn168 |
Ejemplares similares
-
Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report
por: Yamada, Ryo, et al.
Publicado: (2019) -
Renal-Limited Thrombotic Microangiopathy due to Bevacizumab Therapy for Metastatic Colorectal Cancer: A Case Report
por: Toriu, Naoya, et al.
Publicado: (2019) -
Thrombotic microangiopathy with severe renal failure in adenocarcinoma
por: Lakshminarayana, G., et al.
Publicado: (2008) -
A rare case of renal thrombotic microangiopathy associated with Castleman’s disease
por: Mutneja, Anubha, et al.
Publicado: (2017) -
Overlap of Thrombotic Microangiopathy and Mesangial Proliferative Glomerulonephritis Caused by Combination Therapy with Atezolizumab and Bevacizumab
por: Horino, Taro, et al.
Publicado: (2022)